Logo
x

Search

Subscribe Now

BioArctic

BioArctic and Eisai Receives MAA from MHRA for Leqembi (lecanemab) to Treat Early Alzheimer’s Disease (AD) in Great Britain

BioArctic and Eisai Receives MAA from MHRA for Leqembi (lecanemab) to Treat Early Alzheimer’s Disease (AD) in Great Britain

  • August 22, 2024
BioArctic Partner Eisai Reports the MAA Submission to the MHRA for Lecanemab to Treat Early Alzheimer's Disease

BioArctic Partner Eisai Reports the MAA Submission to the MHRA for Lecanemab to Treat Early Alzheimer's Disease

  • May 22, 2023
BioArctic & Eisai’s MAA for Lecanemab Receives Approval from the US FDA to Treat Early Alzheimer's Disease

BioArctic & Eisai’s MAA for Lecanemab Receives Approval from the US FDA to Treat Early Alzheimer's Disease

  • January 27, 2023
BioArctic Partner Eisai Reports MAA Submission of Leqembi (lecanemab) to the EMA for Early Alzheimer's Disease

BioArctic Partner Eisai Reports MAA Submission of Leqembi (lecanemab) to the EMA for Early Alzheimer's Disease

  • January 11, 2023
BioArctic Partner Eisai Reports P-III (Clarity AD) Study Results of Lecanemab for the Treatment of Alzheimer's Disease

BioArctic Partner Eisai Reports P-III (Clarity AD) Study Results of Lecanemab for the Treatment of Alzheimer's Disease

  • September 28, 2022
BioArctic Partner Eisai Report the US FDA Acceptance of BLA for Lecanemab to Treat Alzheimer's Disease

BioArctic Partner Eisai Report the US FDA Acceptance of BLA for Lecanemab to Treat Alzheimer's Disease

  • July 6, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.